Physician profile
John A Lowery
NPI 1255352035
$1,912.42
in general payments reported to CMS, 2019-2025
22 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $16.55 · 2021: $189 · 2022: $126 · 2023: $301 · 2024: $612 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $372.47 | 2021-2025 | Luxor, Simbrinza, Centurion |
| Aerie Pharmaceuticals, INC. | $300.49 | 2019-2021 | |
| Horizon Therapeutics Plc | $208.41 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $157.99 | 2024-2025 | Xdemvy |
| Amgen INC. | $138.61 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $106.65 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $96.76 | 2022-2025 | |
| Dompe US, INC. | $75.46 | 2024-2025 | Oxervate |
| Abbvie INC. | $72.53 | 2022-2024 | |
| Oyster Point Pharma, INC. | $70.54 | 2022-2024 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $70.34 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Optos, INC. | $55.03 | 2019 | |
| Biotissue Holdings INC. | $32.70 | 2022-2023 | |
| Rxsight INC | $24.61 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Genentech USA, INC. | $21.70 | 2023 | Vabysmo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $20.03 | 2022 | |
| Omeros Corporation | $17.34 | 2021 | |
| Ocular Therapeutix, INC. | $16.55 | 2020 | |
| Allergan, INC. | $16.07 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.77 | 2021 | |
| New World Medical,INC. | $11.44 | 2019 | |
| Btg International INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lowery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.